The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2025 | Advancing liquid biopsy in lung cancer: early use and future applications
David O’Reilly, MBBCh, BAO, MSc, MRCPI, of Beaumont RCSI Cancer Centre, Dublin, Ireland, highlights the growing role of liquid biopsy in lung cancer diagnosis and treatment selection. He emphasizes the importance of using liquid biopsy at the earliest possible stage, ideally at a patient’s first healthcare interaction, to improve diagnostic efficiency. Beyond detecting key biomarkers like ALK and EGFR, liquid biopsy may provide insights into co-mutations such as TP53 and STK11. While promising for monitoring minimal residual disease and treatment response, further prospective evaluation is needed before widespread clinical adoption. This interview took place at the BTOG 2025 congress in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
